For clinicians, pharmacists and specialist nurses who want a working understanding of the endocannabinoid system (ECS) and cannabinoid pharmacology without committing to a textbook chapter. The aim here is clinical grounding: enough to interpret prescribing information, evaluate evidence, and counsel colleagues, without overstating what cannabinoid science currently supports.
Why the ECS matters in everyday prescribing
The endocannabinoid system is one of the most widely distributed neuromodulatory systems in the human body. It influences pain processing, mood, appetite, sleep, immune function, motor control and gastrointestinal motility. That breadth explains both why exogenous cannabinoids have such varied effects and why inter-patient response to cannabis-based products for medicinal use (CBPMs) is so heterogeneous. Two patients on the same THC dose can experience very different outcomes, and the ECS is much of the reason.
Clinicians do not need to manipulate the ECS directly to make sensible prescribing decisions. They do, however, need to understand its main components well enough to recognise where a claim is well-supported, where it is plausible but unproven, and where it is marketing.
Core components of the ECS
The receptors: CB1 and CB2
The ECS is built around two G-protein-coupled receptors, CB1 and CB2. CB1 is the most abundant G-protein-coupled receptor in the central nervous system. It is concentrated in the cerebral cortex, hippocampus, basal ganglia, cerebellum, hypothalamus and dorsal horn of the spinal cord. CB1 activation modulates neurotransmitter release — typically inhibitory — at presynaptic terminals, which underlies most of the psychoactive and analgesic effects of THC.
CB2 is concentrated in peripheral tissues, particularly in cells of the immune system: B and T lymphocytes, macrophages, natural killer cells, microglia. It is also expressed at lower levels in some CNS sites and on osteoclasts and osteoblasts. CB2 activation has anti-inflammatory and immunomodulatory effects without the psychoactivity associated with CB1. This receptor distribution is the structural reason why selective CB2-targeting drugs have been pursued in chronic pain and inflammatory disease, though no selective CB2 agonist is in routine UK clinical use.
The endogenous ligands: anandamide and 2-AG
The two principal endocannabinoids are anandamide (N-arachidonoylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG). Both are lipid-derived signalling molecules synthesised on demand from membrane phospholipid precursors rather than stored in vesicles. Anandamide is a partial agonist at CB1 with relatively low binding affinity for CB2; 2-AG is a full agonist at both CB1 and CB2 and is present at substantially higher tissue concentrations.
Both endocannabinoids act primarily as retrograde messengers: released from the postsynaptic neuron, they travel back across the synapse to activate presynaptic CB1 receptors and dampen neurotransmitter release. This retrograde signalling is the system’s main mechanism for fine-tuning excitatory and inhibitory tone.
The metabolising enzymes: FAAH and MAGL
Endocannabinoid signalling is terminated by rapid enzymatic degradation. Anandamide is hydrolysed primarily by fatty acid amide hydrolase (FAAH); 2-AG is hydrolysed primarily by monoacylglycerol lipase (MAGL). The therapeutic interest here is indirect — pharmacological inhibition of FAAH or MAGL would raise endogenous tone without administering an exogenous cannabinoid — but FAAH inhibitor development has had a difficult history (notably the BIA 10-2474 trial in 2016) and no FAAH or MAGL inhibitor is licensed in the UK.
THC: a partial CB1 agonist with a wide effect profile
Delta-9-tetrahydrocannabinol is a partial agonist at CB1 and CB2, with higher affinity for CB1. Most of THC’s effects — analgesia, appetite stimulation, antiemetic action, sedation, the characteristic psychoactive experience, anxiogenic effects at higher doses, tachycardia, orthostatic effects — are mediated by CB1 activation. CB2 contributions are largely peripheral and immunomodulatory.
Clinically relevant features of THC pharmacology:
- Dose-response is non-linear and often biphasic. Low THC doses may produce anxiolytic, sleep-promoting or analgesic effects; higher doses can produce anxiogenic, dysphoric or paranoid responses in the same patient. This biphasic pattern is well documented and is the reason most CBPM titration protocols start at very low doses and increase slowly.
- Lipophilicity drives a long terminal half-life. THC distributes widely into adipose tissue and is released slowly, giving an apparent terminal half-life of 20-30 hours after acute use and considerably longer with chronic use. Plasma concentration peaks, however, are rapid after inhalation.
- Active metabolism. THC is metabolised primarily by CYP2C9 and CYP3A4 to 11-hydroxy-THC, an active metabolite of comparable potency, and then to inactive carboxy-THC. Genetic variation in CYP2C9 explains some inter-patient variability.
CBD: a more complex pharmacological actor than the label suggests
Cannabidiol is often described loosely as “non-psychoactive”. A more accurate description is that CBD is not intoxicating at typical clinical doses but is far from pharmacologically inert. Its primary mechanisms are not classical receptor agonism. CBD is a negative allosteric modulator at CB1, dampening rather than activating the receptor, which is one reason it can attenuate some of THC’s adverse effects when co-administered. It has low direct affinity for CB2.
Beyond the cannabinoid receptors, CBD interacts with a long list of targets at clinically relevant concentrations: serotonergic 5-HT1A receptors (partial agonist), TRPV1 vanilloid receptors, GPR55, PPAR-gamma, and several ion channels. It also inhibits adenosine reuptake. This polypharmacology probably underlies CBD’s anti-seizure activity (the mechanism in Dravet and Lennox-Gastaut syndromes is incompletely characterised but is not principally cannabinoid-receptor mediated) and contributes to its anxiolytic profile in clinical and pre-clinical models.
For prescribing purposes, two CBD facts matter most:
- CBD is a meaningful CYP450 inhibitor. It inhibits CYP3A4 and, more potently, CYP2C19, with smaller effects on CYP2C9. This drives several clinically significant drug interactions, most notably with clobazam — a topic covered in our forthcoming drug-interactions piece.
- The therapeutic dose range is wide. Licensed indications (Epidyolex in epilepsy) use doses up to 10-20 mg/kg/day, far higher than the doses typically encountered in wellness CBD products. Clinicians should not assume that observational data from low-dose consumer CBD translates to the doses used in CBPM practice.
Minor cannabinoids: evidence versus marketing
Cannabigerol (CBG), cannabinol (CBN), cannabichromene (CBC), tetrahydrocannabivarin (THCV) and a longer list of “minor” cannabinoids are increasingly marketed as therapeutic agents in their own right. The clinical evidence picture is uneven and clinicians should treat strong individual claims with caution.
- CBG. Acts on CB1 and CB2 with lower affinity than THC and CBD, and engages alpha-2 adrenergic and 5-HT1A receptors. Pre-clinical signals in inflammatory bowel disease and neuroprotection exist. Human data are very limited.
- CBN. A degradation product of THC, frequently marketed as a “sleep cannabinoid”. Sedative effects in humans are inadequately characterised; controlled human sleep data are minimal.
- CBC. Pre-clinical anti-inflammatory and analgesic signals. No meaningful human evidence base.
- THCV. Behaves as a CB1 antagonist at low doses and partial agonist at higher doses. Pre-clinical interest in metabolic and appetite-suppressant effects. Phase 2 human data are limited.
Where minor-cannabinoid content is highlighted on product literature, the appropriate clinical question is whether the dose actually delivered is plausibly pharmacologically active given what is known. Trace concentrations are unlikely to be clinically meaningful regardless of mechanism claims.
The entourage hypothesis: useful framework or marketing veneer?
The entourage hypothesis proposes that the combined effect of cannabinoids and terpenes in a whole-plant preparation is greater than the sum of the parts, with non-cannabinoid constituents modulating the activity of THC and CBD. The concept originated in peer-reviewed work in the late 1990s and has been popularised by Ethan Russo and others.
The current scientific position is honestly mixed. There is plausible mechanistic support for some terpene contributions to pharmacological effect at physiologically relevant concentrations, and some clinical observation that whole-plant preparations behave differently from isolates at equivalent THC content. But there is also a substantial body of in vitro and pre-clinical work showing that many proposed entourage interactions do not replicate, or only appear at concentrations far above what is delivered in clinical use. Clinicians should view entourage claims as a working hypothesis with partial support, not a settled principle. It is reasonable to factor it into the choice between an isolate and a whole-plant preparation; it is not a reason to assume one preparation is therapeutically equivalent to another.
Tolerance, downregulation and inter-patient variability
Chronic CB1 activation produces receptor downregulation and desensitisation. This is the cellular substrate for cannabis tolerance, and it has practical implications for CBPM patients. Tolerance to THC’s psychoactive and cardiovascular effects develops within days to weeks; tolerance to analgesic and antiemetic effects is more variable and incompletely characterised. Some patients report stable benefit over months to years; others require dose escalation; a smaller group develop reduced response that does not recover with dose increase. Brief drug holidays have been proposed pragmatically to restore receptor sensitivity but are not formally evidence-based.
Inter-patient variability in response to cannabinoids is among the widest of any class of medicines in routine specialist use. Drivers include CB1 receptor polymorphisms (CNR1), CYP2C9 and CYP3A4 variants affecting THC metabolism, FAAH variants affecting endocannabinoid tone, body composition (THC distribution into adipose tissue), age, sex, tobacco co-use, and prior cannabis exposure. Pharmacogenomic testing is not yet routine in UK CBPM practice but explains much of the clinical experience that “the same dose of the same product is a different medicine in different patients”.
What this means for prescribing
- Expect heterogeneity. A starting dose that suits the typical patient may be too much or too little for the patient in front of you. Slow titration is not an over-cautious convention; it reflects the pharmacology.
- Distinguish receptor effects from polypharmacology. CBD’s clinical effects often have little to do with cannabinoid receptors. THC’s effects mostly do. This affects how you predict drug interactions and adverse effects.
- Take CYP-mediated interactions seriously. CBD is a clinically meaningful CYP inhibitor at therapeutic doses; THC contributes additional CYP1A2 induction and CYP2C9 inhibition. The interaction profile is broader than is often appreciated.
- Hold minor-cannabinoid and entourage claims to the same standard you would apply to any medicine. Mechanism plus mouse plus marketing is not a clinical evidence base.
For the related clinical pathway and governance considerations, see our overview of prescribing CBPMs on the UK specialist pathway. For an introduction to MUZO Health’s role in UK supply, visit our About page.
About MUZO Health
MUZO Health was created to raise the standard of cannabis-based medicines in the UK, with a focus on quality, consistency and clinical integrity. Our mission is to support clinicians, empower patients and help move cannabis medicine forward responsibly, transparently and without compromise. Learn more about MUZO Health.